mTOR Inhibition Is Effective against Growth, Survival and Migration, but Not against Microglia Activation in Preclinical Glioma Models

Initially introduced in therapy as immunosuppressants, the selective inhibitors of mTORC1 have been approved for the treatment of solid tumors. Novel non-selective inhibitors of mTOR are currently under preclinical and clinical developments in oncology, attempting to overcome some limitations associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Lisi, Lucia, Pizzoferrato, Michela, Ciotti, Gabriella Maria Pia, Martire, Maria, Navarra, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297872/
https://www.ncbi.nlm.nih.gov/pubmed/37372982
http://dx.doi.org/10.3390/ijms24129834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297872/
https://www.ncbi.nlm.nih.gov/pubmed/37372982
http://dx.doi.org/10.3390/ijms24129834

Ejemplares similares